Neurology

Trofinetide is the first and only drug approved for the treatment of Rett syndrome.

Zavegepant is the only calcitonin gene-related peptide receptor antagonist nasal spray indicated for acute treatment of migraine in adults and can provide pain relief in 15 minutes.

Migraines are common yet misunderstood, therefore it is important that various treatment options be examined and offered to this patient population.

A patient’s neurological symptoms diminished when he discontinued a biosimilar and started various new treatments.

Investigators noted medication prescription disparities among patients with dementia despite factoring for age and sex.

Vitamin D may reduce the risk of dementia because it clears amyloid that accumulates in the brain.

Friedreich’s ataxia is a rare neuromuscular disease that affects approximately 5000 patients in the United States.

Zavegepant is the first calcitonin gene-related peptide receptor for migraines in development as an intranasal formulation studied in a phase 3 trial.

New research from Harvard Medical School could be a game changer for the management of headaches associated with anti-CGRP migraine therapy.

Austedo XR will be available in 3 extended-release tablet strengths, which provides an updated regimen that may result in a lower pill count for patients.

Students may be hesitant to discuss migraines, which can lead to absences, difficulties in personal life, financial burdens, and poor mental health.

Low cognitive functioning and cognitive decline have been linked to an increased risk of morbidity and mortality.

Pimavanserin is an atypical antipsychotic indicated for the treatment of Parkinson disease-associated hallucinations and delusions.

Patients with acute migraines should assess their condition before starting a treatment regimen.

Promising results for lecanemab's efficacy in patients with mild cognitive impairment or mild dementia associated with Alzheimer disease were accompanied by reports of adverse effects associated with treatment.

Researchers noted no significant changes in anxiety or depression between patients who were positive or negative for amyloid deposition.

The model can predict the chronological ages of cognitively normal participants with an average absolute error of 2.3 years, which is about 1 year more accurate than an existing model.

Analysis indicates that Acadia Pharmaceuticals Inc’s pimavanserin is the only FDA-approved medication for the treatment of delusions and hallucinations associated with PDP.

Lecanemab (Lequembi) approved to treat mild cognitive impairment or mild dementia associated with Alzheimer disease.

Indication can play a major role in pharmacists recommending brain health products.

Pharmacological options for those who experience migraines come in the form of abortive or preventative therapies.

Zavegepant could become the first intranasal drug that targets CGRP in migraine sufferers to gain FDA approval.

Coughing is a reflex predominantly mediated by control centers in respiratory areas of the brainstem, which is modulated by the cerebral cortex.

Atogepant is an oral calcitonin gene-related peptide receptor antagonist approved in 2021 for patients with episodic migraines.

With the advent of disease-modifying therapies, the life span of patients with multiple sclerosis has increased dramatically.